Busulfan /kg

Phase 1Small molecule

MMemorial Sloan Kettering Cancer Center

Busulfan /kg is one of 37 small molecule programs targeting Hematologic Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic MalignanciesActive, not recruiting

Hematologic MalignanciesPhase 1

Active, not recruiting

Competition

Competitive Landscape

53 competitors in Hematologic Malignancies

#DrugCompanyPhaseTrials

Avycaz

PPhiladelphia Eye Associates

Approved

1 2

Cellcept

Roche

Phase 2

22 3

Fludara

Sanofi

Phase 2

21 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

28 5

Cytosar

Teva

Phase 2

10 6

Atgam

Novartis

Phase 2

8 7

Trexall

Jazz Pharmaceuticals

Phase 2

7 8

Prograf

VVeloxis Pharmaceuticals

Phase 2

19 9

Alkeran

Adriamycin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Conditioning Prior to Ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04098393·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Busulfan /kg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Busulfan /kg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Busulfan /kg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMemorial Sloan Kettering Cancer Center

Busulfan /kg

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hematologic Malignancies1 trial

References

Drug Info

Quick Facts

Related News